



**CENTRO DE  
INGENIERIA GENETICA  
Y BIOTECNOLOGIA**  
PATENT DEPARTMENT

**CIGB**  
Apartado 6162, CP 10600  
Ciudad Habana, Cuba  
Tel. (53-7) 271 8008  
Fax. (53-7) 271 8070/33 6008  
271 4764

**CONFIRMATION COPY**

To:	<b>INTERNATIONAL PRELIMINARY EXAMINATION AUTHORITY EUROPEAN PATENT OFFICE</b>	From	<b>CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA Patent Department</b>
Fax No.	49-89 2399 / 4465	Our Fax	(53-7) 2713364 / 2718070 2714764 / 336008
Date	October 30, 2003	Pages	3 including this
Your ref.	PCT CU03/00002	Our ref.	CU2002/0020
RE:	Response to the WRITTEN OPINION. International Application Number PCT CU03/00002. International Filing Date: 22/01/2003 Priority Date: 24/01/2002		

Dear Sirs;

Thank you for your Invitation to reply to the PCT Written Opinion concerning the above-referred international application.

Regarding the examiner opinion of the patent application PCT/CU03/00002 referred to the enhanced or increase levels of the grow hormone in circulation by the action of the

peptide GHRP6, it has been accordingly shown in the description of our application as previous art, (see Pag. 1, Ln. 14 - 17), as well as others molecules related with the same effect, (see Pag. 2, Ln. 7 - 10, Ln. 20 - 25, Ln. 26 - 30). In our case we are referring to the peptide GHRP6 specific action mediated by the growth stimulation in relation to the resistance, particularly of aquatic organism, to diseases.

**In Reference to Doc. US 5 767 124 A (KAUFMAN MICHAEL J ET AL),  
marked as (Y).**

COLUMN 16, LINE 25 - 31

COLUMN 16, LINE 34 - 35

COLUMN 17, LINE 6

This document is referred to the use in humans and animals in general of peptides combination, to enhance or increase the levels of the endogenous growth hormone. In our case we are referring to the GHRP6 alone, mean not combined, for the use particularly in aquatic organisms specifically for the control of the disease resistance, (see Pag. 3, Ln. 17 - 18, Pag. 5, Ln. 25 - 28, example No.3 and claims No.1, 10, 11, 12, 13 y 14), where the guiding mechanisms are particularly different from the rest of the animals, because of its own genetic characteristics and molecular mechanisms.

**In Reference to Doc. ES 2 005 224 A (EASTMAN KODAK CO),  
marked as (Y).**

This document is referred to the use of peptides combination, from the group I, II and III. In our case we are referring to the GHRP6 from group II alone, mean not combined, for the use particularly in aquatic organisms specifically for the control of the disease resistance, (see Pag. 3, Ln. 17 - 18, Pag. 5, Ln. 25 - 28, example No.3 and claims No.1, 10, 11, 12, 13 y 14), where the guiding mechanisms are particularly different from the rest of the animals, because of its own genetic characteristics and molecular mechanisms.

Pag. 6, Ln. 28 - 29 y Pag. 6, Ln. 43, Pag. 14, Ln. 39 - 40 y Ln. 55.

*Referred to peptide GHRP6.*

Pag. 2, Ln. 60 – 63 y Pág. 3

The referred peptides are not related with our peptide.

Pag. 7, Ln. 6 – 7

The referred peptides are not related with our peptide.

Pag.12, Ln 47 – 59

*Is referred to peptides combination, which is not our case.*

*Is referred also to peptides that act through out the hormone release grow hormone receptor. In our case the pathway is different.*

Pag. 15, Ln. 19 – 20

The referred peptides are not related with our peptide.

Claim No. 1

*Is referred to the combination of at least two groups of different polypeptides. In our case we are referring to the GHRP6 alone, mean not combined.*

*Is referred also to any hormone from the hormone release grow hormones and with the functional equivalents of the sane. In our case we use the peptide GHRP6, which does not belong to the group of the hormone release grow hormones.*

*Is referred also to peptides that act through out the hormone release grow hormone receptor. In our case the pathway is different.*

In this way, we expect to overcome the arguments stated in this Written Opinion dealing with novelty or inventive step in light of the documents cited in the International Search Report.

Best regards,

Lic. Argia Poveda Marcheco  
Representante Legal  
Departamento de Patentes  
Centro de Ingeniería Genética y Biotecnología  
Ave. 31 e/ 158 y 190, Cubanacán, Playa 10600  
Ciudad de la Habana, Cuba  
Tel. 537 2718008-8164-8466  
Fax. 5372718070  
email: paten@cigb.edu.cu